Blog
About

6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pulmonary arterial hypertension associated with interferon therapy: a population-based study

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Isolated cases of pulmonary arterial hypertension (PAH) with interferon α or β therapy have been reported, but no population-based estimates of the incidence of the disease after interferon exposure are available. The aim of this study was to determine the incidence of PAH after initiation of interferon therapy, using a large commercial insurance database.

          Methods

          Using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes, we utilized the Clinformatics™ Data Mart (CDM) database to identify subjects between 20 and 65 years old who received α or β interferon therapy between April 2001 and December 2012. Patients were followed from one year prior to the first medication claim for interferon to the first diagnosis of pulmonary hypertension using ICD-9-CM codes 416.0 and 416.8, or disenrollment. In those subjects diagnosed with pulmonary hypertension, a prescription for PAH-specific medications was used as a surrogate endpoint.

          Results

          We identified 20,113 subjects who received interferon therapy during the study period. The median follow-up was 20 months. Pulmonary hypertension occurred in 71 subjects, and PAH-specific medications were prescribed to 7 of these subjects.

          Conclusion

          Although our analysis showed that the development of PAH is a rare event with interferon therapy, the risk of developing the disease is several fold higher than that for the general population.

          Related collections

          Author and article information

          Contributors
          +1-409-772-3123 , Ravikanth.papani@gmail.com
          aduarte@utmb.edu
          y1ulin@utmb.edu
          yokuo@utmb.edu
          gusharma@utmb.edu
          Journal
          Multidiscip Respir Med
          Multidiscip Respir Med
          Multidisciplinary Respiratory Medicine
          BioMed Central (London )
          1828-695X
          2049-6958
          17 January 2017
          17 January 2017
          2017
          : 12
          Affiliations
          [1 ]Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas Medical Branch, John Sealy Annex 5.140, 301 University Boulevard, Galveston, TX 77555 USA
          [2 ]Office of Biostatistics, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX USA
          Article
          82
          10.1186/s40248-016-0082-z
          5240202
          © The Author(s). 2017

          Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

          Categories
          Original Research Article
          Custom metadata
          © The Author(s) 2017

          Respiratory medicine

          pulmonary arterial hypertension, interferons, drug toxicity

          Comments

          Comment on this article